Session

IBD (Posters)

PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE ULCERATIVE COLITIS PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY
PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE ULCERATIVE COLITIS PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY

IBD (Posters)  et al.

SYSTEMATIC REVIEW ON THE USE OF ENTERAL NUTRITION FOR THE INDUCTION OF REMISSION IN PAEDIATRIC CROHN’S DISEASE
SYSTEMATIC REVIEW ON THE USE OF ENTERAL NUTRITION FOR THE INDUCTION OF REMISSION IN PAEDIATRIC CROHN’S DISEASE

IBD (Posters)  et al.

THE CORRELATION BETWEEN 6-THIOGUANINE NUCLEOTIDE CONCENTRATIONS AND LEUKOCYTE FRACTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING THIOPURINE TREATMENT
THE CORRELATION BETWEEN 6-THIOGUANINE NUCLEOTIDE CONCENTRATIONS AND LEUKOCYTE FRACTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING THIOPURINE TREATMENT

IBD (Posters)  et al.

BENEFICIAL EFFECTS OF NATURAL MINERAL WATERS ON INTESTINAL INFLAMMATION AND THE MUCOSA-ASSOCIATED MICROBIOTA
BENEFICIAL EFFECTS OF NATURAL MINERAL WATERS ON INTESTINAL INFLAMMATION AND THE MUCOSA-ASSOCIATED MICROBIOTA

IBD (Posters)  et al.

A 12-WEEK TAILORED PHYSICAL TRAINING PROGRAM INCLUDING DIETARY ADVICE IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: A RANDOMIZED CROSSOVER TRIAL.
A 12-WEEK TAILORED PHYSICAL TRAINING PROGRAM INCLUDING DIETARY ADVICE IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: A RANDOMIZED CROSSOVER TRIAL.

IBD (Posters)  et al.

IMPACT OF EXCLUSIVE ENTERAL NUTRITION ON INTESTINAL HOMEOSTASIS IN A MOUSE MODEL OF COLITIS
IMPACT OF EXCLUSIVE ENTERAL NUTRITION ON INTESTINAL HOMEOSTASIS IN A MOUSE MODEL OF COLITIS

IBD (Posters)  et al.

ROLE OF P2X7 IN INTESTINAL FIBROSIS AND INFLAMMASOME ACTIVATION: RELEVANCE IN CROHN´S DISEASE
ROLE OF P2X7 IN INTESTINAL FIBROSIS AND INFLAMMASOME ACTIVATION: RELEVANCE IN CROHN´S DISEASE

IBD (Posters)  et al.

IN CONTRAST TO ORAL IRON THERAPY, INTRAVENOUS IRON THERAPY IS NEITHER INFLUENCED BY, NOR DOES IT EXACERBATE, SYSTEMIC INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
IN CONTRAST TO ORAL IRON THERAPY, INTRAVENOUS IRON THERAPY IS NEITHER INFLUENCED BY, NOR DOES IT EXACERBATE, SYSTEMIC INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH
UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH

IBD (Posters)  et al.

BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS
BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS

IBD (Posters)  et al.

REAL-LIFE EFFECTIVENESS AND SAFETY OF USTEKINUMAB INDUCTION THERAPY FOR KOREAN PATIENTS WITH CROHN’S DISEASE: A KASID PROSPECTIVE MULTICENTER STUDY
REAL-LIFE EFFECTIVENESS AND SAFETY OF USTEKINUMAB INDUCTION THERAPY FOR KOREAN PATIENTS WITH CROHN’S DISEASE: A KASID PROSPECTIVE MULTICENTER STUDY

IBD (Posters)  et al.

PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOULD BE VACCINATED AGAINST PNEUMOCOCCUS AND INFLUENZA DESPITE IMMUNOSUPPRESSIVE THERAPY
PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOULD BE VACCINATED AGAINST PNEUMOCOCCUS AND INFLUENZA DESPITE IMMUNOSUPPRESSIVE THERAPY

IBD (Posters)  et al.

INFLIXIMAB PHARMACOKINETIC PEAK CO AND 1-WEEK SERUM LEVELS PREDICT 8-WEEK TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
INFLIXIMAB PHARMACOKINETIC PEAK CO AND 1-WEEK SERUM LEVELS PREDICT 8-WEEK TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY
PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY

IBD (Posters)  et al.

COLONIC MUCOSA BARRIER DEFECTS IN COLLAGENOUS AND ISCHEMIC COLITIS
COLONIC MUCOSA BARRIER DEFECTS IN COLLAGENOUS AND ISCHEMIC COLITIS

IBD (Posters)  et al.

BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

IDENTIFYING PATIENTS WITH INFLAMMATORY BOWEL DISEASES UNDER SUBCUTANEOUS BIOTHERAPY USING A MEDICATION DISPENSE DATABASE: FEASIBILITY, AND IMPACT OF COVID-19
IDENTIFYING PATIENTS WITH INFLAMMATORY BOWEL DISEASES UNDER SUBCUTANEOUS BIOTHERAPY USING A MEDICATION DISPENSE DATABASE: FEASIBILITY, AND IMPACT OF COVID-19

IBD (Posters)  et al.

INVOLVEMENT OF MACROPHAGES IN THE ACTIVATION OF MESENCHYMAL EPITHELIAL TRANSITION IN CROHN'S DISEASE: ROLE OF THE MICROENVIRONMENT
INVOLVEMENT OF MACROPHAGES IN THE ACTIVATION OF MESENCHYMAL EPITHELIAL TRANSITION IN CROHN'S DISEASE: ROLE OF THE MICROENVIRONMENT

IBD (Posters)  et al.

TOFACITINIB IN ULCERATIVE COLITIS: SHORT TERM OUTCOMES IN REAL WORLD EXPERIENCE IN THE SOUTH OF SPAIN
TOFACITINIB IN ULCERATIVE COLITIS: SHORT TERM OUTCOMES IN REAL WORLD EXPERIENCE IN THE SOUTH OF SPAIN

IBD (Posters)  et al.

CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB
CHARACTERIZATION OF CYTOKINE AND DRUG CONCENTRATIONS IN SERUM, MUCOSA AND FAECES DURING INDUCTION TREATMENT OF SEVERE ULCERATIVE COLITIS WITH INFLIXIMAB

IBD (Posters)  et al.

Item 521 - 540 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
27
28 29